Liberator Medical Holdings to Be Acquired by C. R. Bard for Approximately $181 Million

STUART, FL--(November 20, 2015) - Liberator Medical Holdings, Inc. ("Liberator") (NYSE MKT: LBMH), a leading national direct-to-consumer provider of quality medical supplies through its subsidiary, Liberator Medical Supply, Inc., today announced that it has entered into a definitive agreement to be acquired by C. R. Bard, Inc. (BCR), for a cash purchase price of $3.35 per fully-diluted share, or approximately $181 million in the aggregate.

The purchase price represents a 36% premium over Liberator's average closing price during the 90 trading days ended November 19, 2015. The transaction is expected to close in the first quarter of 2016, subject to approval by Liberator's shareholders, satisfaction of customary closing conditions and receipt of certain regulatory approvals.

Advanced Accelerator Applications S.A. Announces Pricing of Initial Public Offering

NEW YORK, NY / ACCESSWIRE / November 10, 2015 / Advanced Accelerator Applications S.A. ("AAA" or the "Company"), an international specialist in Molecular Nuclear Medicine (MNM), today announced the pricing of its initial public offering of 4,688,000 American Depositary Shares ("ADSs") representing 9,376,000 of its ordinary shares at a price of $16.00 per ADS. The ADSs are expected to begin trading on the Nasdaq Global Select Market on November 11, 2015 under the ticker "AAAP." All of the ADSs are being offered by AAA. In addition, AAA has granted the underwriters a 30-day option to purchase up to 703,200 additional ADSs from the Company at the initial public offering price, less underwriting discounts.

Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and JMP Securities LLC are acting as co-managers.

Abaxis Reports Financial Performance for the Second Quarter of Fiscal 2016

UNION CITY, Calif., Oct. 27, 2015 -- Abaxis, Inc. (ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the second fiscal quarter ended September 30, 2015.

Second quarter overview:

• Revenues from continuing operations of $56.0 million, up 11% over last year's comparable quarter.
• Diluted EPS from continuing operations of $0.34, up 36% over last year's comparable quarter.
• Diluted EPS, including discontinued operations, of $0.34, up 42% over last year's comparable quarter.

  Published: 28 October 2015

  Written by Editor

  Nasdaq   Financial Results   Up on News  

  Read more: Abaxis Inc ( ABAX )

Nobilis Health Corp. Announces Second Quarter Results; Provides Guidance

HOUSTON, TX--(Aug 14, 2015) - Nobilis Health Corp. (NYSE MKT: HLTH) (TSX: NHC) ("Nobilis" or the "Company") today announced its financial results for the three and six months ended June 30, 2015. All dollar amounts are in United States currency unless otherwise stated; percentage calculations are based on the numbers in the financial statements and may not correspond to rounded figures presented in this release.

Chris Lloyd, Nobilis Health's CEO, said, "We are excited to announce that the Company's second quarter recorded total revenues were $48.9 million with an Adjusted EBITDA¹ (net of NCI) of $7.1 million. This represents a significant improvement over the corresponding period in 2014, during which the Company's total revenues were $15.1 million, with an Adjusted EBITDA¹ of $0.9 million.